DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The DNA damage response (DDR) network maintains genomic stability by coordinating DNA repair and cell-cycle checkpoints.
• DDR defects drive genomic instability and tumor development, but also present therapeutic vulnerabilities.
• PARP inhibitors exploit homologous recombination repair defects in tumors, leading to approved therapies.

Purpose of the Study:

• To analyze lessons learned from PARP inhibitor development for DDR-targeting drugs.
• To explore reasons for the limited success of other DDR inhibitor classes.
• To suggest strategies for improving the development of novel DDR-targeting cancer therapies.

Main Methods:

• Review of historical and current clinical trial designs for DDR inhibitors.
• Analysis of predictive biomarker requirements for DDR-targeted therapies.
• Exploration of monotherapy and combination study models, including combinations with anti-angiogenic or immune checkpoint inhibitors.

Main Results:

• Despite extensive research, only PARP inhibitors have been approved, with few other DDR inhibitors reaching late-stage trials.
• A critical need exists for more reliable predictive biomarkers to guide DDR-targeted therapy selection.
• Current study designs may not be optimal for evaluating novel DDR inhibitors.

Conclusions:

• Leveraging insights from PARP inhibitor development is crucial for advancing new DDR-targeting drugs.
• Improved biomarker strategies and innovative clinical trial designs are essential for therapeutic success.
• Simultaneous targeting of multiple DDR pathways and combination strategies hold promise for enhanced cancer treatment.